Global Liver Diseases Therapeutics Market to 2019 - With F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck Dominating the Market
DUBLIN, Oct. 15, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/hfrlrr/global_liver) has announced the addition of the "Global Liver Diseases Therapeutics Market 2015-2019" report to their offering.
This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.
Based on disease indication, the market is segmented as follows:
- Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
- Liver cirrhosis
- Liver cancer
- Hepatitis (Hepatitis A, B, and C)
The report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Market landscape
PART 07: Market segmentation by disease
PART 08: Global hepatitis therapeutics market
PART 09: Global liver cancer therapeutics market
PART 10: Global nonalcoholic fatty liver disease therapeutics market
PART 11: Global liver cirrhosis therapeutics market
PART 12: Market segmentation by type of molecule
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Key vendor analysis
PART 21: Appendix
For more information visit http://www.researchandmarkets.com/research/hfrlrr/global_liver
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article